AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$PSTV

PLUS THERAPEUTICS, INC.

Price · $PSTVvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $PSTV in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $PSTV in the last 30 days.

Top stories · $PSTVMore →
APR 7·BlockonomiHigh

Plus Therapeutics (PSTV) Stock: CNSide Diagnostic Secures AMA Billing Code Despite Share Decline

Despite a 4.80% decline in its stock price, Plus Therapeutics (PSTV) announced a significant milestone: its CNSide diagnostic system has secured a dedicated AMA billing code (0640U), effective July 1, 2026. This proprietary code will streamline reimbursement processes for the cerebrospinal fluid tumor cell diagnostic, enhancing its commercial infrastructure and market penetration in CNS oncology. The CNSide platform helps identify malignant cells in CSF, addressing a critical need in treating metastatic central nervous system malignancies.

APR 1·The Manila Times

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Plus Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards, consisting of stock options and restricted stock units, were issued under the Company's 2015 New Employee Incentive Plan and approved by the Compensation Committee as required by Nasdaq Rule 5635(c)(4) to entice new talent. The awards vest over several years, contingent on continued employment.

MAR 26·Investing.com India

Plus Therapeutics appoints Ron Andrews to board of directors By Investing.com

Plus Therapeutics, Inc. (NASDAQ:PSTV) has appointed Ron Andrews to its Board of Directors, bringing over 35 years of experience in the diagnostics industry. Andrews has a strong background in capital raising and exits, having served in leadership roles at Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher. This appointment comes as the company faces financial challenges, with its stock having declined significantly over the past year, though InvestingPro analysis suggests it is slightly undervalued.

News on $PSTV

All news →